Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer

Overview

Journal Transl Oncol

Specialty Oncology

Date 2016 Jun 9

PMID 27267845

Citations 3

Authors

Lana Ghanipour

Spyros Darmanis

Ulf Landegren

Bengt Glimelius

Lars Pahlman

Helgi Birgisson

Affiliations

Soon will be listed here.

Abstract

Background: In the search for prognostic biomarkers, a significant amount of precious biobanked blood samples is needed for conventional analyses. Solid-phase proximity ligation assay (SP-PLA) is an analytic method with the ability to analyze many proteins at the same time in small amounts of plasma. The aim of this study was to explore the potential use of SP-PLA for biomarker validation in patients with colorectal cancer (CRC).

Material And Methods: Plasma samples from patients with stage I to IV CRC, with (n = 31) and without (n = 29) disease dissemination at diagnosis or later, were analyzed with SP-PLA using 35 antibodies targeting an equal number of proteins in 5-μl plasma samples. Carcinoembryonic antigen (CEA), analyzed earlier in this cohort using a different technology, was used as a reference.

Results: A total of 21 of the 35 investigated proteins were detectable with SP-PLA. Patients in stage II to III with disseminated disease had lower plasma concentrations of HCC-4 (P = .025). Low plasma levels of tissue inhibitor of metalloproteinases-1 were seen in patients with disseminated disease stage II (P = .003). The level of CEA was higher in patients with disease dissemination compared with those without (P = .007).

Conclusion: SP-PLA has the ability to analyze many protein markers simultaneously in a small amount of blood. However, none of the markers selected for the present SP-PLA analyses gave better prognostic information than CEA.

Citing Articles

Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer.

Birgisson H, Tsimogiannis K, Freyhult E, Kamali-Moghaddam M Transl Oncol. 2018; 11(4):1034-1043.

PMID: 29982101 PMC: 6037900. DOI: 10.1016/j.tranon.2018.05.012.

International scientific communications in the field of colorectal tumour markers.

Ivanov K, Donev I World J Gastrointest Surg. 2017; 9(5):127-138.

PMID: 28603585 PMC: 5442406. DOI: 10.4240/wjgs.v9.i5.127.

Monitoring of the Immune Dysfunction in Cancer Patients.

Santegoets S, Welters M, van der Burg S Vaccines (Basel). 2016; 4(3).

PMID: 27598210 PMC: 5041023. DOI: 10.3390/vaccines4030029.

References

Guiducci C, Di Carlo E, Parenza M, Hitt M, Giovarelli M, Musiani P . Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol. 2004; 172(7):4026-36. DOI: 10.4049/jimmunol.172.7.4026. View

Christodoulou S, Alexopoulou D, Kontos C, Scorilas A, Papadopoulos I . Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumour Biol. 2014; 35(5):4673-85. DOI: 10.1007/s13277-014-1612-y. View

Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt M . Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol. 2009; 27(3):585-91. DOI: 10.1007/s12032-009-9253-5. View

Ghanipour A, Jirstrom K, Ponten F, Glimelius B, Pahlman L, Birgisson H . The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):2949-56. DOI: 10.1158/1055-9965.EPI-09-0456. View

Wallin U, Glimelius B, Jirstrom K, Darmanis S, Nong R, Ponten F . Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer. 2011; 104(10):1619-27. PMC: 3101900. DOI: 10.1038/bjc.2011.112. View

Huh J, Oh B, Kim H, Kim Y . Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol. 2010; 101(5):396-400. DOI: 10.1002/jso.21495. View

Birgisson H, Nielsen H, Christensen I, Glimelius B, Brunner N . Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer. 2010; 46(18):3323-31. DOI: 10.1016/j.ejca.2010.06.009. View

Mian B, Dinney C, Bermejo C, Sweeney P, Tellez C, Yang X . Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003; 9(8):3167-75. View

Darmanis S, Nong R, Vanelid J, Siegbahn A, Ericsson O, Fredriksson S . ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS One. 2011; 6(9):e25583. PMC: 3183061. DOI: 10.1371/journal.pone.0025583. View

10.

Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, Kamali-Moghaddam M . Protein biomarker validation via proximity ligation assays. Biochim Biophys Acta. 2013; 1844(5):933-9. DOI: 10.1016/j.bbapap.2013.07.016. View

11.

Figueredo A, Rumble R, Maroun J, Earle C, Cummings B, McLeod R . Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003; 3:26. PMC: 270033. DOI: 10.1186/1471-2407-3-26. View

12.

Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S . Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011; 39(15):e102. PMC: 3159481. DOI: 10.1093/nar/gkr424. View

13.

Weng W, Feng J, Qin H, Ma Y . Molecular therapy of colorectal cancer: progress and future directions. Int J Cancer. 2014; 136(3):493-502. DOI: 10.1002/ijc.28722. View

14.

Oconnell M, Mailliard J, Kahn M, Macdonald J, Haller D, Mayer R . Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997; 15(1):246-50. DOI: 10.1200/JCO.1997.15.1.246. View

15.

. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264(11):1444-50. View

16.

Birgisson H, Wallin U, Holmberg L, Glimelius B . Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer. 2011; 11:438. PMC: 3209454. DOI: 10.1186/1471-2407-11-438. View

17.

Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K . ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23(10):2479-2516. DOI: 10.1093/annonc/mds236. View

18.

Nong R, Wu D, Yan J, Hammond M, Gu G, Kamali-Moghaddam M . Solid-phase proximity ligation assays for individual or parallel protein analyses with readout via real-time PCR or sequencing. Nat Protoc. 2013; 8(6):1234-48. DOI: 10.1038/nprot.2013.070. View

19.

Dymicka-Piekarska V, Kemona H . Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration?. Thromb Res. 2009; 124(1):80-3. DOI: 10.1016/j.thromres.2008.11.021. View

20.

Duffy M, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L . Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2013; 134(11):2513-22. PMC: 4217376. DOI: 10.1002/ijc.28384. View